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Available online 10 March 2016Cancer cells frequently up-regulate DNA replication and repair proteins such as themultifunctional DNA2 nucle-
ase/helicase, counteracting DNA damage due to replication stress and promoting survival. Therefore, we hypoth-
esized that blocking both DNA replication and repair by inhibiting the bifunctional DNA2 could be a potent
strategy to sensitize cancer cells to stresses from radiation or chemotherapeutic agents. We show that homozy-
gous deletion of DNA2 sensitizes cells to ionizing radiation and camptothecin (CPT). Using a virtual high through-
put screen, we identify 4-hydroxy-8-nitroquinoline-3-carboxylic acid (C5) as an effective and selective inhibitor
of DNA2. Mutagenesis and biochemical analysis deﬁne the C5 binding pocket at a DNA-binding motif that is
shared by the nuclease and helicase activities, consistent with structural studies that suggest that DNA binding
to the helicase domain is necessary for nuclease activity. C5 targets the known functions of DNA2 in vivo: C5 in-
hibits resection at stalled forks aswell as reducing recombination. C5 is an evenmore potent inhibitor of restart of
stalled DNA replication forks and over-resection of nascent DNA in cells defective in replication fork protection,
including BRCA2 and BOD1L. C5 sensitizes cells to CPT and synergizes with PARP inhibitors.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cancer1. Introduction
DNA replication is the central process of all actively dividing cells.
Blocking this process can result in cell cycle arrest, senescence, and ap-
optosis. Therefore, DNA replication forks are the targets of most cancer
chemotherapeutics, including agents that induce DNA lesions, such as
camptothecin (CPT) and cisplatin, plus those that stall forks, such asthecin; DNA2, DNA2 nuclease/
tic mobility shift assay; EXO1,
se 1; HDR, homology direct re-
onic stem;MSFC, Multiple Stage
mental Therapeutics Program;
, single-strand annealing; SSB,
l@caltech.edu (J.L. Campbell),
. This is an open access article undergemcitabine and 5-ﬂuorouracil (Le Tourneau et al., 2010). In addition,
radiotherapy (RT), which is used to treat ~50% of all cancers, induces
DNA damage. If not repaired, this DNA damage may block or collapse
DNA replication forks and kill cancer cells (Begg et al., 2011). However,
a drawback of these therapies is that the cancer cell may become resis-
tant to the radiation or chemotherapy. Reasons for resistance include in-
creased tolerance for DNA lesions, and enhanced capacity for DNA
damage response and repair. Many cancer cells that are resistant to RT
or chemotherapeutic drugs have abnormally high DNA repair capacity,
and inhibition of DNA repair has successfully sensitized the cancer
cells to cytotoxicity from chemotherapeutic drugs.
One major conserved DNA repair enzyme is the DNA2 helicase/nu-
clease (DNA2). Complete inactivation of either the helicase or nuclease
activity of DNA2 in cells from awide range of organisms, including yeast
and humans, induces cell cycle arrest and cell death (Budd and
Campbell, 1995; Kang et al., 2000; Kim et al., 2005; Duxin et al., 2009,
2012;Wawrousek et al., 2010; Karanja et al., 2012; Lin et al., 2013). Dis-
ruption of DNA2 has been associated with human disease. A splice-sitethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Seckel syndrome, a primordial dwarﬁsm syndrome. Other mutations
are linked to breast cancers (Strauss et al., 2014). Interestingly, the
DNA2-deﬁcient Seckel cells show markers of senescence, where cells
are viable but cease to proliferate (Shaheen et al., 2014).
DNA2 plays three key roles that allow the cancer cells to resist the in-
trinsic and extrinsic DNA replication stresses induced by chemotherapy
or RT (radiotherapy): ﬂap removal during DNA replication, double-
strand break (DSB) resection during repair, and stabilization and restart
of reversed replication forks (Wanrooij and Burgers, 2015). During rep-
lication, DNA2 removes the long 5′ RNA/DNA “ﬂaps” that arise during
Okazaki fragment processing in difﬁcult-to-replicate genomic regions
(Bae et al., 2001; Budd and Campbell, 1997; Kang et al., 2010; Kao
et al., 2004a, b; Masuda-Sasa et al., 2008; Stewart et al., 2008, 2010).
In yeast, ScDNA2 is probably themajor nuclease for RNA primer remov-
al during Okazaki fragmentmaturation, in collaborationwith ﬂap endo-
nuclease 1 (FEN1 or Rad27) (Bae et al., 2001; Budd andCampbell, 1997).
For DSB repair, DNA2 acts in one of the two major DSB resection path-
ways. DNA2 acts with the Bloom Syndrome (BLM) helicase or Werner
Syndrome (WRN) helicase in DSB end resection at a critical early step
after licensing by limited cleavage by the MRN/CtIP complex (Budd
et al., 2005; Imamura and Campbell, 2003; Zhu et al., 2008; Budd and
Campbell, 2009; Niu et al., 2009; Cejka et al., 2010; Nimonkar et al.,
2011; Symington and Gautier, 2011; Sturzenegger et al., 2014; Liao
et al., 2008, 2011). BLM (or WRN), moving on the 3′ terminated strand,
unwinds the duplex end to create a “fork”; DNA2 acts as a nuclease on
the complementary strand and degrades the 5′ end to produce 3′
ssDNA tails for strand invasion during homology-directed repair
(HDR) and S phase checkpoint activation. This resection activity func-
tions in parallel to and independently of resection by Exonuclease 1
(EXO1), downstream of MRE11 (Shibata et al., 2014). At stalled replica-
tion forks, DNA2 acts to stabilize, repair and restart forks to allow com-
pletion of replication (Hu et al., 2012; Karanja et al., 2014; Thangavel
et al., 2015; Weitao et al., 2003a, b). DNA2 also acts in signaling, as
both an activator and a target of checkpoint kinases. For instance,
DNA2 is required to directly activate the yeast master signaling kinase
ATR (Kumar and Burgers, 2013). Furthermore, DNA2 is a target of
checkpoint effector kinase Rad53/Chk1/2, and is required to regulate
potentially deleterious fork reversal and template switching during rep-
lication fork stalling in yeast and humans (Hu et al., 2012; Lai and Foiani,
2012; Thangavel et al., 2015). DNA2 can also play a negative role when
the RAD51, BRCA1, BRCA2 and the FA/BRCA (Fanconi anemia/Breast
cancer) pathway is impaired (Hashimoto et al., 2010; Schlacher et al.,
2011, 2012; Petermann et al., 2010). Like MRE11, which functions up-
stream of DNA2, DNA2 is involved in the excessive resection seen in
cells deﬁcient in fork protection (Karanja et al., 2014; Wang et al.,
2015; Higgs et al., 2015). Thus, DNA2 must be highly regulated to pro-
tect genome stability. In this work, we describe a potent inhibitor of
these DNA2 DNA replication and repair activities that sensitizes cancer
cells to chemotherapies.
Mechanistically, DNA2 is well studied, but nevertheless poorly de-
ﬁned. Biochemical and genetic experiments have demonstrated an in-
tricate interaction between the nuclease and helicase (Bae et al., 2001;
Budd and Campbell, 2000, 2009; Kao et al., 2004a, b; Levikova et al.,
2013). Furthermore, biochemical studies indicate that there is a major
DNA binding site interacting at the junction of the ﬂap and downstream
duplex DNA that is required for both the nuclease and helicase activities
(Stewart et al., 2010). Which motifs in the DNA2 protein govern this
major binding site have been elusive, but the inhibitor work we report
here clariﬁes these relationships and both provides functional support
and is in turn supported by the recently published X-ray crystal struc-
ture of murine DNA2 (Zhou et al., 2015). The conclusions of our mech-
anistic studies using the inhibitor correlate with the multi-domain
interaction of DNA2 with DNA revealed in the X-ray crystal structure
ofmurineDNA2 (Zhou et al., 2015), and ourmutational studies of inhib-
itor susceptibility speciﬁcally provide functional support for the modelproposed for the role of helicase domain DNA binding contacts in nucle-
ase activation in that study (Zhou et al., 2015).
2. Materials & Methods
2.1. 3-D Modeling of Human DNA2 and High Throughput Virtual Screening
of the Inhibitors
The methodology for 3-D modeling of human DNA2 and high
throughput virtual screening of the inhibitors has been described in
the Results section.
2.2. Protein Puriﬁcation and Nuclease Activity Assay
All WT and mutant DNA2 proteins in this study were expressed as
3X Flag-tagged recombinant proteins in 293T cells and were puriﬁed
using afﬁnity chromatography as previously described (Ronchi et al.,
2013). The nuclease assay was conducted as previously described
(Zheng et al., 2008).
2.3. ATPase Assays and EMSA Assays
The ATPase assay was conducted as previously described (Masuda-
Sasa et al., 2006). WT DNA2 nuclease cleaves the DNA substrate,
which makes it technically difﬁcult to display the helicase and ATPase
activities. We therefore chose to use the D294Amutant, which is defec-
tive in nuclease activity but has similar ATPase activity to WT DNA2, to
test the inhibitory effects of C5 (Masuda-Sasa et al., 2006). The EMSA
was performed as described previously (Hellman and Fried, 2007).
2.4. InhibitionMode andNonlinear Regression to Determine the Inhibitor Ki
See detailed methods in the on-line supplemental experimental
procedures.
2.5. Cell Culture, Measurement of IC50, Clonogenic Assay, and Cell
Proliferation Assay
See detailed methods in the on-line supplemental experimental
procedures.
2.6. Immunoﬂuorescence Staining
Cells (on cover-slips) with or without various drug treatments for
24 h were ﬁxed with 4% paraformaldehyde, permeabilized with 0.1%
Triton X100, blockedwith the Image iT FX signal enhancer (Invitrogen),
and incubated (1.5 h, room temperature) with the indicated primary
antibodies. The antibodies against γ-H2AX and phosphorylated RPA2
were from Sigma Aldrich. The cells were then washed with PBS buffer
and incubated (1 h, room temperature)with the corresponding second-
ary antibodies (1:200, Invitrogen). The slides were then washed with
PBS buffer, counter stained with DAPI and analyzedwith a ﬂuorescence
microscope (Olympus AX70).
2.7. DSB Repair Reporter Assays
HDR-GFP and SSA-GFP were integrated in U2OS cells (Gunn and
Stark, 2012; Howard et al., 2015). The U2OS cells were transfected
with the I-SceI expression vector, or the empty vector and GFP vector
as negative and positive controls, respectively. At 3 h after transfection,
we changed the culturemedium to freshmediumwith orwithout com-
pound C5, and cultured the cells for 3more days. The cellswere harvest-
ed and the GFP+ frequencies (repair frequencies) were determined by
ﬂow cytometry using a CyAn ADP Analyzer (Beckman Coulter, Inc.).
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See detailed methods in the on-line supplemental experimental
procedures.
2.9. Knockdown of Gene Expression in MCF7, A549, and U2OS Cells
Cells were transfected with scrambled siRNA oligos (siControl) or
siRNA oligos against human DNA2, BOD1L, and BRCA2 (Sigma). The
residual protein levels were detected by western blot.
3. Results
3.1. Elimination of the DNA2 Gene Sensitizes Cells to Radio- and Chemo-
Therapeutic Agents
We were interested in DNA2 as a target of inhibition because yeast
and human cells that are depleted of DNA2 are sensitive to agents that
cause replication stress, such as CPT and cisplatin (Budd and
Campbell, 2000; Karanja et al., 2012; Peng et al., 2012). DNA2 is recruit-
ed to ionizing-radiation (IR)-induced subnuclear foci in chicken and
human cell lines (Hoa et al., 2015). To further investigate the biological
roles of DNA2 in mammals, we established DNA2 knockout (dna2−/−)
mouse ES (MES) cells. The dna2−/−MES cells were viable, presumably
due to backup repair pathways, perhaps involving EXO1, as in yeast; al-
though their proliferation rate was approximately 50% of the WT MES
cells. To investigate if DNA2 knockout caused the cells to bemore sensi-
tive to DNA damaging agents, we treated WT and dna2−/− MES cells
with γ-irradiation (IR) and CPT and observed that dna2−/−MES cells
were signiﬁcantly more sensitive than WT cells to both IR and CPT
(Figure S1a and S1b). Taken togetherwith previouswork, these ﬁndings
suggested that DNA2 is a useful candidate for sensitizing cancer cells to
DNA damage-inducing therapeutic agents.
3.2. Virtual High Throughput Screening and Experimental Validation for
Inhibitors of DNA2
We employed a three-dimensional structural model for virtual
screening of small molecules that bind to DNA2. The homology model
for the DNA2 helicase domain was based on the crystal structures of
the Upf1–RNA U15 complex (PDB 2XZL (Chakrabarti et al., 2011)) and
the human Upf1–ADP complex (PDB 2GK6 (Cheng et al., 2007)),
which have high sequence identity with DNA2. Although the sequence
identity (30%) between DNA2 and Upf1 was at the lower limit for ho-
mology modeling, we were able to successfully build the Upf1-based
DNA2 model structure (Fig. 1a). (See also Ref. Ronchi et al. (2013) for
an earlier version of the model.) After aligning the DNA2 helicase
domain with UPF1, the homology model was built with the SWISS-
MODEL tool and reﬁned with the Schrodinger Protein Preparation
Wizard toﬁxmissing residues andhydrogen positions (Fig. 1a).Wepre-
dicted druggable sites on theDNA2model using an in-house-developed
Druggable Site Prediction by FDA-approved drugs (DSP) methodology,
which uses a diverse subset of 100 FDA-approved drug molecules to
dock around the protein surface and predict best binding sites on the
protein surface. The deﬁnition of the “best binding site” is based on
the numbers of the tested drugs bound to the protein pockets.We iden-
tiﬁed three docking pockets for screening, designated as Sites 1, 2, and 3
with 53%, 24%, and 12% of the tested drugs bound to them, respectively
(Fig. 1a). Sites 1 and 3 are predicted tomake close contactwithDNAand
Site 2 is close to the ATP binding and hydrolysis motifs of the helicase
domain. The proposed Site 3 is composed of the limited residues con-
served between DNA2 and UPF1 in the N-terminal model sequence
and interacts with the DNA and Site 1 (Fig. 1a). More importantly, mo-
lecular dynamics simulation results further indicated the DNA2 model
was stable and reasonable,making it a good choice for in silico screening
of DNA2 small molecule inhibitors. Reﬁnement of the structure bymolecular dynamics simulation showed that the site centers are stable
and that the N-terminal domain stays as shown in Fig. 1b. The average
root-mean-square deviation (RMSD) of site centers was only 2–3 Å dur-
ing simulation, although the RMSD of some ﬂexible loop regions could
bemore than15Å,which indicates that thepredicted sites are stabilized
to allow ligand binding. Based on an alignment of helicase family mem-
bers (Cheng et al., 2007), there are seven highly conserved helicasemo-
tifs including I, Ia, II, III, IV, V, and VI in DNA2. The I, II, and IV motifs are
for ATP binding and hydrolysis, whereas the Ia, III, and V motifs are the
DNA binding domains in other helicases. Domains IV and VI coordinate
the DNA unwinding and hydrolysis. One predicted site of drug binding,
Site 1, contains amino acids in the Ia motif. Site 2 contains residues in
motif I, as well as in motifs V and VI (Fig. 1c). This information allowed
us to focus our search for candidate DNA2 inhibitors on the most likely
smallmolecule binding sites. It also guidedus to a pocket thatmight fur-
ther illuminate how DNA2 interacts with its DNA substrate.
We then conducted a virtual high throughput screening (vHTS) for
molecules binding to Site 1 because Site 1 gave the best FDA drug screen
score and is predicted to affect DNAbinding,making it a favorable target
site. Our model also suggested that Site 1, which interacts with Site 3,
might be a shared component of both the helicase and nuclease activity
and that inhibitors bound to Site 1 might clarify the coordination of the
nuclease and helicase activities of DNA2. We used an in-house-devel-
oped Multiple-Stage Full-Coverage (MSFC-VS) algorithm to screen an
in silico a library of 260,071 compounds from the National Cancer Insti-
tute Developmental Therapeutics Program (NCI DTP) library for binding
to Site 1. This generated a list of 40 compounds (Table S1). Although Site
1 is located in the putative helicase domain, we chose to search for
inhibitors that might affect both the nuclease and helicase activities,
because previous studies suggested that they may compete for the
same DNA binding site. We therefore screened these compounds bio-
chemically for their inhibition of DNA2 nuclease activity using puriﬁed
recombinant hDNA2 and a well-deﬁned ﬂap substrate. Among the 40
identiﬁed compounds, 4molecules inhibited theDNA2nuclease activity
(Fig. 1d and Table S1). Among these compounds, 4-hydroxy-8-
nitroquinoline-3-carboxylic acid, designated as compound C5, had the
top Glide XP Docking Score (−8.3 kcal/mol), and displayed the highest
cytotoxicity to human cancer cells (Fig. 1e and Table S1). To determine if
C5 speciﬁcally targets DNA2, we tested if C5 will inhibit the enzyme ac-
tivities of two similar structure speciﬁc nucleases, FEN1 and EXO1. We
found that C5 poorly inhibited the activities of the other two nucleases,
in contrast to DNA2 (Figure S1c–f). Taken together, C5 is a speciﬁc inhib-
itor of DNA2 nuclease activity in vitro.
3.3. Kinetic Analysis of C5 in Inhibiting DNA2 Activity
In order to determine the IC50 of C5 for inhibition of the nuclease ac-
tivity of DNA2, we conducted kinetic analyses. Using a ﬂap DNA sub-
strate, we ﬁrst studied the time course of the nuclease activity in order
to determine the proper time interval for kinetic analysis at various sub-
strate concentrations (Figure S2a). We found that the enzyme activity
was linear at 1–10 min, and we conducted the assays in this range. To
evaluate the mechanism of inhibition of nuclease activity by C5, we
measured the nuclease activity of DNA2 at various concentrations of in-
hibitor and substrate (Fig. 2a). Using a Lineweaver-Burk plot, we evalu-
ated the competition patterns using competitive, noncompetitive, and
uncompetitive models. The competitive inhibition model ﬁts best to
the inhibition data with C5. To extract the intrinsic inhibition constant
of C5 for DNA2, we obtained apparent inhibition constant, or IC50,
values, for C5 at a series of substrate concentrations (Fig. 2b). Extrapola-
tion of the observed IC50 values to limiting substrate concentrations, as
described in the Materials & Methods section, gave an inhibition con-
stant of 20 μM (Fig. 2c).
The kinetic studies suggested that C5 acts as a competitive inhibitor
of DNA2 nuclease activity. A competitive model predicts C5 binding to
DNA2 should block binding of DNA2 to the DNA substrate. Consistent
Fig 1.Threedimensional humanDNA2model and potential pockets for screening smallmolecule DNA2 inhibitors (see also Figures S1 and Table S1). a. A homologymodel for humanDNA2
in complex with single-stranded DNA (ssDNA). Orange: ssDNA; Cyan: nuclease domain; Green: ATP binding domain; Pink: helicase domain. Three potential drug binding pockets are
speciﬁed as Sites 1–3. b. Reﬁnement of the DNA2 model structure by molecular dynamics simulation (50 ns). Root mean square deviation (RMSD) values during simulation at three
potential drug binding sites are shown as ﬂuctuating bars. The secondary structures of the sites are represented by color, which is speciﬁed at the bottom of the graph. c. The linear
domain and motif structures and the drug binding sites of human DNA2. Upper panel: the DNA2 functional domain structure; Middle panel: the three putative drug binding sites; and
Bottom panel: the secondary structure motifs. d. Inhibition of DNA2 nuclease activity by chemical compounds that were selected from the virtual screen. Recombinant ﬂag-tagged
DNA2 (10 nM) was mixed with 32P-labeled ﬂap DNA substrates (500 fmol) in the absence or presence of the potential DNA2 binding chemical compound (250 μM each). The image
shows a representative biochemical reaction (37 °C, 15 min) that was resolved using 15% denaturing polyacrylamide gel electrophoresis (PAGE). The locations of substrates and
products on the gel are indicated. e. The chemical name and structure of C5.
76 W. Liu et al. / EBioMedicine 6 (2016) 73–86with themodel, we found that C5 inhibited the ATPase activity of DNA2,
which is dependent on DNA binding (Fig. 2d and e). To further test this
model, we evaluated DNA2 substrate binding in the presence of various
C5 concentrations directly, by electrophoretic mobility shift assay
(EMSA). We found that DNA2 effectively bound ﬂap DNA substrates,
leading to reduced electrophoretic mobility; but the addition of C5 re-
duced the formation of the DNA2–substrate complex (Fig. 2f and g).
The inhibitor concentration needed to reduce theDNA2–substrate com-
plex formation to 50% is 30 μM, which is comparable to the IC50 valuefor inhibition of theDNA2 nuclease activity. Finally, we tested the ability
of C5 to inhibit DNA2 helicase activity. Using the DNA2 helicase sub-
strate in which an M13 phage DNA is hybridized to a 5′ tailed oligonu-
cleotide (Masuda-Sasa et al., 2006), we found, as expected by our
ﬁnding of inhibition of DNA-dependent ATPase activity, that C5 inhibits
the 5′ to 3′, end–dependent DNA helicase activity of DNA2 (Figure S2b,
compare lanes 3 and 6, 4 and 7, 5 and 8) (Masuda-Sasa et al., 2006;
Balakrishnan et al., 2010). Based on our results, we suggest that al-
though our homology structure does not show the nuclease domain,
Fig. 2. Inhibitory kinetics of DNA2 nuclease activity, and C5 inhibitory effects to ATPase activity andDNA substrate binding capacity (see also Figure S2). a–c. The nuclease activity of DNA2
was analyzed in the presence of varying concentrations of DNA2enzyme (0.5–5 nM),ﬂapDNA substrate (5–50 nM), andDNA2 inhibitors C5 (0–250 μM). a. Lineweaver-Burk plot of DNA2
nuclease activity in the presence of various concentrations ofﬂapDNA substrate (x axis) and C5 (μM, designated as [I]). b. DNA2 nuclease activity in the presence of various concentrations
of compound C5 (x axis) and ﬂapDNA substrate (nM, designated as [S]). The C5 concentration (IC50observed) that inhibits 50% of theDNA2nuclease activity at a given concentration of DNA
substrates is indicated with dotted lines. The inhibited nuclease activities were normalized to the DMSO control, set as 1. c. Plot of IC50observed versus [S] for determination of IC50. The
values of IC50observed obtained from panel B and corresponding DNA substrate concentrations were plotted. When [S] is zero, the derived corresponding IC50observed value is the
theoretical IC50 of C5. In panels a–c, the values are means ± s.d of three independent experiments. d. The representative TLC image showing C5 inhibition of the ATPase activity of
DNA2. The DNA2 enzyme concentration used was 10 nM; ATP substrate concentration used was 200 μM; DNA concentration used was 200 nM; the inhibitor C5 concentrations used
was in a range of 0 to 250 μM. e. Quantiﬁcation of inhibition of DNA2 in the ATPase activity, the relative ATPase activities normalized to DMSO control. The values shown are the
means ± s.d. of three independent assays. f. The representative EMSA image showing C5 inhibition of DNA2 binding to the DNA substrate. The DNA2 enzyme concentration used was
50 nM; the 32P labeled DNA concentration used was 1 nM; the compound C5 concentrations used ranged from 0 to 1000 μM. g. Quantiﬁcation of inhibition of DNA2 substrate binding,
the relative binding activities normalized to DMSO control. The values shown are the means ± s.d. of three independent assays.
77W. Liu et al. / EBioMedicine 6 (2016) 73–86that contacts in both ATPase and helicase domains are required for
nuclease activity, consistent with the recent X-ray crystal structure of
murine DNA2 (80% identical to human DNA2) (Zhou et al., 2015).
3.4. Validation of Site 1 on DNA2 as the Binding Pocket for C5 and Rationale
for its Effect on DNA Binding
C5 was identiﬁed by virtual screening for small molecules that bind
to a pocket (Site 1) near the DNA binding site in our computational
DNA2 model, which superimposes on the DNA binding site in theX-ray crystal structure. Based on our 3-D model, we searched the resi-
dues within 6 Å spheres around the predicted C5 binding site. We iden-
tiﬁed multiple residues, including V682, L686, F696, L697, R698, L699,
G700, L729, L732, Y733, Q736, Q738, V739, and T741, that may play a
key role in coordinating C5 binding (Fig. 3a). Superposition of our
model for human DNA2 on the mouse DNA2 structure, shows that
these putative C-5 interacting amino acids could directly affect those in-
volved in DNA binding (Zhou et al., 2015). To test if C5 indeed binds to/
affects the putative pocket at Site 1,we substituted residues predicted to
be near C5 with alanine. The mutant and WT DNA2 proteins were
78 W. Liu et al. / EBioMedicine 6 (2016) 73–86puriﬁed and the nuclease activities were assayed. Although Site 1 lies in
the helicase domain, many of the mutations altered the nuclease activ-
ity in the absence of inhibitor, presumably because the Site 1 pocket is
close to the putative DNA substrate binding pocket. These are the ﬁrst
mutations within the helicase domain that have been demonstrated to
concomitantly affect the nuclease activity, strengthening our results
for dual DNA2 helicase and nuclease inhibition by C5. Other mutants,
however, maintained intact nuclease activity (Figure S3a and S3b). We
chose F696A and L732A with enzyme activity similar to the WT to test
their sensitivity to compound C5. Both the nuclease activity and DNA
binding activity of the two mutants were less sensitive to C5 than wild
type (Fig. 3b and c and Figure S3c). The compound C5 IC50s for nuclease
activities and DNA substrate binding were greater than 250 μM
for F696A and L732A, compared to 30 μM for the WT. This suggests
that the mutations impair the interaction of C5 with the designated
binding site (Site 1) of DNA2 and that this site does affect substrate
DNA binding in the helicase portion of DNA2 that is critical for nuclease
activity.Fig. 3.DNA2mutations at Site 1 impair C5 inhibition of DNA2nuclease activity (see also Figure S
left panel shows a cartoon view and the right panel shows a surface view of Site 1. The C5 inhibi
are cyan and 736–745 are light-blue. b. The 14 residues within 6 Å spheres around compound
affect the nuclease activity of DNA2 (Figure S3), reduced C5 inhibition of DNA2 nuclease activi
various concentrations of C5 (indicated as [I] in a range from 0 to 250 μM) and quantiﬁed, the
control where the relative nuclease activity was set as 1. The values shown are the means ± s
resistant to C5 inhibitor. We added DMSO without the inhibitor C5 as a control where the rela
DNA concentration used was 1 nM. The inhibitor C5 concentrations ranged from 0 to 125 μM.3.5. C5 Displays On-Target Effects on DNA2
Next, we determined the cytotoxicity of DNA2 inhibitor C5 and eval-
uatedwhether the compoundhad on-target effects onDNA2 in cultured
cells.We havemeasured IC50 values of C5with a panel of 18 cell lines of
4 major types of cancers by a cell proliferation assay (Chou, 2010). The
IC50 values among the different cell lines varied from 7 μM to 70 μM,
which is comparable to the estimated enzymatic IC50 value of 20 μM
(Fig. 4a). Furthermore, we considered that if the toxic effects of C5
were due to targetingDNA2, then cells lackingDNA2 should be resistant
to the effects of compound C5. As anticipated, we found a reduced spon-
taneous survival rate in human and mouse cells with either shRNA-
mediated knockdown (Fig. 4b) or knockout (Fig. 4c) of DNA2. We
found that WT MES cells and human MCF7 cancer cells treated with
C5 showed a 60% survival rate, compared to the untreated WT control
(Fig. 4b and c), a result similar to the effects of DNA2 knockdown and
knockout. Importantly, we found that treatment of dna2−/− MES or
DNA2 knockdown human cancer cells with C5 did not further reduce3). a. Three dimensional structure of the Site 1 smallmolecule binding pocket of DNA2. The
tor is shown as a pink stick. The residues 680–691 are green, 692–710 are orange, 729–735
C5 that form Site 1 pocket were identiﬁed. Among them, F696A and L732A, which did not
ty. The nuclease activity of WT, F696A, and L732A (1 nM) was assayed in the presence of
DNA substrate concentration was 15 nM. We added DMSO without the inhibitor C5 as a
.d. of three independent experiments. c. The DNA binding activity of F696A and L732A is
tive binding activity was set as 1. The DNA2 enzyme concentration used was 50 nM. The
The values shown are the means ± s.d. of three independent experiments.
Fig. 4. IC50 and on-target cytotoxic effects of C5 in human cancer cells andmouse embryonic stem (MES) cells (see also Figure S4). a. IC50 values of C5with a panel of 18 cell lines from 4
major types of cancers. Human non-cancerous or cancer cellswere seeded on a 96-well plate and incubated in culturemedium containing 0 to 80 μMC5 for 7 days. The IC50was calculated
using theCompuSyn software(Chou, 2010). Values are the average of two independent assays. b. Control (shSCR) or DNA2knockdownMCF7cellswere cultured inmedium containing 0 or
1 μMC5 for 4 days. The live cells were counted. The cell survival was calculated by normalizing the number of live cells from each culture to that of the control MCF7 cells (shSCR), which
was arbitrarily set as 100. c. The same experiment as in A was performed on MES cells fromWT and DNA2 knockout mice, which were cultured in medium containing 0 or 1 μM C5 for
4 days. The values shown are the means ± s.d. of three experiments.
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knockdown displayed strong potentiation in cell killing (Figure S4b).
These ﬁndings suggest that the cytotoxic effects of compound C5 were
primarily due to speciﬁc effects on DNA2 at the given concentration.
This suggests that due to residual viability, those normal cells may be
less sensitive to inhibitors than cancer cells, with repair and checkpoint
defects. This also suggests that other enzymes, such as FEN1, EXO1, or
Mre11 cannot completely compensate for the loss of DNA2, indicating
that DNA2 inhibitors are likely to have signiﬁcant physiological effects
in cancer cells. The results suggest that C5 is a potent and speciﬁc inhib-
itor of DNA2 and that virtual docking is a valid method to help identify
DNA2-speciﬁc drugs.
3.6. C5 Suppresses Key DNA2 DNA Replication and Repair Functions
To further validate C5 as a DNA2 inhibitor, we tested its effects on
DNA2 functions known to be affected by knockdown or deletion of
DNA2 in previous studies (Peng et al., 2012; Howard et al., 2015;
Karanja et al., 2012, 2014).Weﬁrst determined the effect of C5 on two re-
combination pathways, SSA (single-strand annealing) and homologous
recombination (HR), using I-SceI/GFP-based reporter assays (Gunn and
Stark, 2012; Howard et al., 2015; Bryant et al., 2009; Pierce et al., 1999).
Since these pathways are most active in S/G2 (Figure S5a), we deter-
mined GFP positive cells in the G2 population. We found that both SSA
and HR were reduced by C5 in a dose-dependent manner (Fig. 5a). For
comparison, at 60 μM C5, SSA and HR were reduced to the same level
as in an siRNA DNA2 knockdown carried out in parallel (Figure S5b).
We next wanted to verify if the defects in recombination assays
were due to inhibition of end resection. During the early steps ofrecombination, DNA2 in complex with BLM or WRN protein resects
DSB ends, producing ssDNA 3′ overhangs (Karanja et al., 2012;
Nimonkar et al., 2011; Sturzenegger et al., 2014). The ssDNA overhangs
are coated with RPA, which is then phosphorylated by ATR (Zou and
Elledge, 2003). To measure resection, we determined the level of phos-
phorylated RPA2 (S33 or S4/8) in cells treatedwithC5 in thepresence or
absence of CPT. CPT stabilizes cleavable complex intermediates in topo-
isomerase I reactions which collapse into DSBs when encountered by a
replication fork (Hsiang et al., 1989; Patel et al., 2012). CPT increased
phosphorylated RPA2 (P-RPA), as measured on western blots and by
immunoﬂuorescence of P-RPA2 foci (Fig. 5b–e). C5 signiﬁcantly
reduced the CPT-induced P-RPA level in γH2AX-positive cells (Fig. 5b–
e). The level of C5 used here reduced RPA phoshporylation to the
same extent as we observed in parallel studies using siRNA DNA2
knockdown (compare Fig. 5c–e and f–h) consistent with previous re-
ports (Duxin et al., 2009, 2012; Karanja et al., 2012; Peng et al., 2012).
Interestingly, we also noted that C5 alone caused background increase
in γH2AX (Fig. 5b–h), presumably because the DNA2 inhibitor itself
causes replication stress, similarly as shown previously for shDNA2
knockdown (Duxin et al., 2009, 2012; Karanja et al., 2012).
When DNA replication forks are stalled in S-phase, DNA2 plays an
important role in stabilizing the stalled forks, in preventing DSB forma-
tion, and in resection of the nascent strand to prepare for the restart of
replication (Karanja et al., 2012; Thangavel et al., 2015; Weitao et al.,
2003a, b; Hu et al., 2012). A recent study using DNA ﬁber assays indicat-
ed that knockdown of DNA2 by siRNAs inhibits replication fork restart
in HU-treated cells or cells treated with low levels of CPT (Thangavel
et al., 2015).We have conducted DNA ﬁber assays to evaluate the effect
of C5 on restart of forks treatedwith low levels of CPT, which in contrast
Fig. 5. Inhibitor C5 suppresses resection-related homology directed repair (HDR) and single-stand annealing (SSA) and causes accumulation of phosphorylated RPA foci (see also
Figure S5). a. C5 inhibits HDR and SSA frequency. The U2OS cells carrying the GFP reporter gene for HDR or SSA assay were transfected with I-Sce I expression vector. The cells were
then incubated in medium containing 0, 10, 20, 40, and 60 μM C5. After 72 h, the cells were harvested and the GFP positive cells were analyzed by ﬂow cytometry. In the DNA2
knockdown experiment, the U2OS cells were transfected with 10 nM of scrambled or DNA2 siRNA oligos for 24 h. The cells were then transfected with the I-SceI expression vector.
After 48 h, the cells were harvested and the GFP positive cells were analyzed by ﬂow cytometry. Knockdown of DNA2 in the engineered U2OS cells was conﬁrmed by western blot
(Figure S5b). Values are mean ± s.d. of three independent experiments. b. DNA2 inhibition by siRNA or C5 impairs replication fork-related DNA end resection in MCF7 cells at similar
levels. MCF7 cells were untreated or treated with 10 μM C5 for 24 h (left panels) or treated with scrambled siRNA (siControl) or siRNA against DNA2 (siDNA2) for 72 h (right panels).
The knockdown efﬁciency of DNA2 was checked by western blotting. The cells were then treated with 1 μM CPT for 4 h. The levels of γ-H2AX and phosphorylated RPA (S33) were
analyzed by western blot using antibodies against γH2AX (Millipore) and phosphorylated RPA (S33) (Abcam). Total level of RPA and β-actin were used as controls, which were
detected using antibodies against RPA32 (Abcam) and β-actin (GeneTex). c–h. DNA2 inhibition by siRNA or C5 impairs replication fork-related DNA end resection in A549 cells at
similar levels. A549 cells were untreated or treated with 10 μM C5 for 24 h (c-e) or treated with scrambled siRNA (siControl) or siRNA against DNA2 (siDNA2) for 48 h (f–h panels).
The knockdown efﬁciency of DNA2 was checked by western blotting (Figure S5). The cells were then treated with 1 μM CPT for 4 h. Panels c and f: Representative images. Panels d, e,
g, and h: Quantiﬁcations: the levels of γ-H2AX and phosphorylated RPA (S33) were quantiﬁed by ImagePro Premier, and the relative P-RPA or γH2AX per nucleus was calculated.
Values are means ± s.d. of three independent assays.
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81W. Liu et al. / EBioMedicine 6 (2016) 73–86to high CPT levels does not cause DSBs but results in increased positive
supercoiling and fork slowing and stalling (Ray Chaudhuri et al., 2012),
or with HU, which inhibits production of nucleotide precursors. In ab-
sence of C5, 80% or 75% of replication forks could restart (red–green
tracts) in HU-treated or CPT-treated cells, respectively (Fig. 6a). Howev-
er, 20 μM C5 reduced the percentage of restarting forks to 60% and 50%
in the HU-treated or CPT-treated cells, respectively (Fig. 6a). This level
of inhibition at 20 μM C5 was equivalent to knockdown of DNA2 using
siRNA (Fig. 6b). These results extend previous studies on DNA2 func-
tions during replication restart (Ray Chaudhuri et al., 2012; Thangavel
et al., 2015; Teicher, 2008) and show that DNA2 is more sensitive to in-
hibition at stalled replication forks than at a single DSB (Fig. 5). C5 also
inhibited restart in cells treatedwith high levels of CPT, resulting in rep-
lication associated DSBs (Figure S6a).
Fork protection is a DNA break repair-independent pathway sup-
pressing genomic instability (Schlacher et al., 2011, 2012). The fork pro-
tection pathway is mediated by BRCA2, BRCA1, RAD51, members of the
Fanconi anemia pathway, and BOD1L. In the absence of any of these fac-
tors, excessive nascent DNA degradation occurs at stalled replication
forks. This degradation is prevented if the end-resection protein
MRE11 is inhibited either by siRNA knockdown or by inhibition of
MRE11 nuclease by the small molecule mirin (Schlacher et al., 2011,
2012). MRE11 functions upstream of DNA2 in resection of double-
strand breaks, and DNA2, in addition to MRE11 has been implicated in
over-resection at stalled replication forks in BOD1L and in RAD51 im-
paired cells, since over-resection is suppressed by knockdown of
DNA2 in the absence of BOD1L or in a RAD51 mutant cell line (Higgs
et al., 2015; Wang et al., 2015). To determine if C5, like DNA2 knock-
down, suppressed nascent DNA degradation and resulting accumula-
tion of ssDNA at stalled forks, we monitored phospho-RPA (P-RPA)
foci in BRCA2- or BOD1L-depleted or mock transfected U2OS cells
with and without HU treatment (Fig. 6c and d). In the absence of HU,
in mock-depleted cells we saw few cells with greater than 15 P-RPA
foci/per cell, and neither mirin nor C5 signiﬁcantly decreased the num-
ber of P-RPA positive cells, consistent with the fork protection pathway
being intact (Fig. 6c). After treatment of the BRCA2- or BOD1L-depleted
U2OS cells with HU, which stalls forks but is not expected to produce
DSBs (Schlacher et al., 2011, 2012; Petermann et al., 2010), and which
are fork protection defective, we observed a dramatic increase in P-
RPA positive cells indicative of nascent DNA degradation upon treat-
ment with HU (Fig. 6c and Figure S6b). This degradation was sup-
pressed by C5. The potency of C5 was estimated by comparing the
effect of mirin, the MRE11 inhibitor, in the same experiment. Remark-
ably, 20 μM C5 has a comparable potency to 50 μM mirin in reducing
this degradation (Fig. 6c, d). To exclude off-target effects of mirin in
our experiments, we showed that another potent MRE11 inhibitor,
PFM39 (Shibata et al., 2014), reduced P-RPA foci to the same extent as
mirin in the BRCA2-deﬁcient cells (Fig. 6d). Finally, we showed in a par-
allel experiment that the level of reduction in P-RPA foci caused by C5 in
BRCA2-deﬁcient cells is also equivalent to that observed in a DNA2
knockdown (Fig. 6d and Figure S6b). Our results are in keeping with
previouswork showing that knockdown of DNA2 counteracts excessive
nascent strand degradation in both BOD1L and in RAD51 impaired cells
(Higgs et al., 2015; Wang et al., 2015). Importantly, extending previous
reports, we show that MRE11 and DNA2 both are responsible for
degrading stalled replication forks in fork protection defective cells, in-
cluding BOD1L and BRCA2. We conclude that C5 suppresses the fork
protection defect of the BRCA2- or BOD1L-deﬁcient cells by inhibition
of DNA2. Taken together, the data shows that C5 is a speciﬁc inhibitor
of DNA2 activities at stalled replication forks in vivo.
3.7. C5 Sensitizes Cells to PARP Inhibitors
To test our hypothesis that inhibition of DNA2 synergizes with other
chemotherapeutic agents, we treated cells with CPT and C5. We found
the two agents to be synergistic for cellular lethality (Fig. 7a). Thesedata uncover the potential for C5 in increasing killing efﬁciencies of
DNA damaging chemotherapeutics.
PARPs have been shown to play an important role in DNA single-
strand break (SSB) repair and at stalled replication forks (Bryant et al.,
2009; Yang et al., 2004; Hu et al., 2014; Ying et al., 2012), and inhibition
of PARPs resulted in accumulation of SSBs and consequent DSBs in the
cells (Fisher et al., 2007; Okano et al., 2003). More recently, PARPs
have also been implicated in loading DNA damage response proteins
to DSB sites (Hu et al., 2014; Li and Yu, 2013). Because DNA2 appears
to function in many of the same pathways as the BRCA breast cancer
genes, including DSB repair and replication fork protection, and PARP
inhibition shows synthetic lethality with BRCA1 or BRCA2 mutants
(Fathers et al., 2012; Fong et al., 2008), we considered that PARP inhibi-
tion might increase the effectiveness of the DNA2 inhibitor. To test this
hypothesis, we determined the survival of MCF7 breast cancer cells cul-
tured in the medium containing compound C5 and/or MK4827, a PARP
inhibitor (Jones et al., 2009). We found that MK4827 and C5 had a
strong synergistic effect in inhibiting the survival of MCF7 cells
(Fig. 7b and c). The IC50 for MK4827 and C5 was 0.8 μM and 1.9 μM.
The combination index for MK4827 (1 μM) and C5 (2 μM) was 0.13, in-
dicating a very strong synergy between two drugs. These data support a
model where DNA2 and PARP collaboratively participate or have com-
plementary roles in DNAdamage response, DSB repair, BER repair path-
ways, and replication fork protection, which will be an important issue
to dissect in future studies.
4. Discussion
We have used a partial DNA2 protein structure based on the homol-
ogy between the helicase domain of DNA2 and yeast Upf1–RNA U15
complex and human Upf1–ADP complex (Chakrabarti et al., 2011;
Cheng et al., 2007) to identify 3 well deﬁned pockets (Sites 1, 2, and
3), where drug like molecules can preferentially dock. We then used a
virtual screen consisting of docking of 260,721NCI deposited smallmol-
ecules to these sites to identify DNA2 inhibitors. This screen is similar to
a previous virtual screen used to identify inhibitors of ribonucleotide re-
ductase (Chen et al., 2015; Zhou et al., 2013). We characterized one in-
hibitor, C5,whichwedemonstrate biochemically inhibits nuclease, DNA
dependent ATPase, helicase, and DNA binding activities of DNA2.
Through a series of functional analyses, we have pinpointed the speciﬁc
functions of DNA2 that C5 targets to explain its cellular toxicity. C5 sup-
presses replication-coupled DSB end resection and restart of either HU-
or CPT-stalled DNA replication forks. C5 also inhibits over-resection of
nascent DNA in cells defective in replication fork protection, such as
BRCA2. All these data support our conclusion that virtual screening
can be efﬁcient, and that C5 is a promising lead compound to develop
sensitizers for cancer chemotherapeutics that cause replication stress.
It is interesting to note that C5, which our model and data suggest
binds to the helicase domain of DNA2, can suppress the nuclease activ-
ity. We propose that this occurs because C5 can reduce DNA substrate
binding to a site in the helicase domain necessary to activate the nucle-
ase. The dramatic effect of the inhibitor on the nuclease activity, its pre-
dicted binding site, and more importantly, the effect of mutations we
identiﬁed in helicase domain 1A on the nuclease activity and DNA bind-
ing reveal that the DNA binding site in helicase domain 1A (counterin-
tuitively) is indeed critical for nuclease activity. This in turn suggests
that DNA contacts in the nuclease site are not sufﬁciently strong to pro-
mote nuclease activity; multiple domains of DNA2 have to interact with
DNA to elicit nuclease activity. These major new insights into the struc-
ture/function mechanism of this important class of enzyme, fused
helicase/nuclease (including AddAB and RecB), extend recent reports
on the X-ray crystal structure of murine DNA2 (80% identity to human
DNA2 in the helicase domain)(Zhou et al., 2015). The structure shows
DNA threading through a tunnel in the enzyme, ﬁrst contacting the nu-
clease. The helicase domain follows and binding occurs as domain 1A
and then 2A contact the DNA in the tunnel (Zhou et al., 2015). This
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(Bae et al., 2002; Balakrishnan et al., 2010; Kao et al., 2004a). Our work
in turn provides direct evidence for requirement for both these domains
for nuclease and helicase activity. Taken together with previous bio-
chemical studies (Kao et al., 2004a; Bae et al., 2002; Stewart et al.,
2010; Balakrishnan et al., 2010), a “thread, bind, and cleave” model
now best explains how DNA2 nuclease works. C5 could either block
threading, so that domain 1A does not come into contact with DNA or
C5 could block binding to 1A or 2A. While we know about the active
sites, the inhibitor will be useful in studying the role of the helicase,
which is still conjectural. Co-crystals of DNA2 with C5 should be veryinformative with respect to the mechanism we propose for C5 function
based on the putative binding to Site 1 in our homology structure. The
putative common DNA binding site, predicted by our results and
shown in the crystal structure, explains how the nuclease and helicase
compete for the same substrate, as proposed by Levikova et al.
(Levikova et al., 2013) and that the nuclease catalytic site contacts
must be disrupted for helicase to be activewhen duplex DNA is encoun-
tered. Therefore, in addition to possible therapeutic uses, the C5 inhibi-
tor and well-designed derivatives will be valuable in future studies of
how the helicase and nuclease activities are co-regulated and
integrated.
Fig. 7.DNA2 inhibitor C5 synergistically kills breast cancer cellsMCF7with CPT and PARP inhibitorMK4827. a. C5 sensitizesMCF cells to CPT. Clonogenic assayswere conducted to evaluate
the survival rate of MCF cells treatedwith different concentrations of CPT in the absence or presence of C5 (1 μM). The survival rate of the cells treatedwith various concentrations of CPT
was calculated by normalizing the number of colonies to that of the cells without CPT treatment. The survival rate of the cells without CPT treatment was arbitrarily set as 1. The values
shown are the means ± s. d. of three independent experiments. b–c. The synergy between the DNA2 inhibitor C5 and the PARP inhibitor MK4827 was assayed by clonogenic assay. The
values are means± s.d. of three independent clonogenic assays. The IC50 and combination index (CI) was calculated using the Compusyn program. b. Representative inhibition curve of
varying concentrations of C5 from 0 to 10 μM in combination with MK4827 (0 or 1 μM). c. Representative inhibition curve of varying concentrations of MK4827 from 0 to 1 μM in
combination with C5 (0 or 2 μM).
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dence that has accumulated that a major, and not minor, function of
DNA2 both in yeast and human is to participate in the protection, re-
modeling and restart of stalled replication forks. We ﬁrst reported this
whenwe showed, using 2D gels, that yeast dna2-1mutants led to repli-
cation fork collapse or remodeling into intermediates thought to be chi-
structured (recombination) intermediates or reversed forks and DSBs,Fig. 6. C5 suppresses restart of stalled DNA replication forks and over-resection of nascent DNA i
fork restart at similar levels as DNA2 knockdown. a. A549 cells were mock or pretreated with
indicated drugs (20 μM C5, 150 nM CPT or 2 mM HU) or drug combinations (20 μM C5 com
(green) for 40 min. Percentage of restarting forks (red-green tracks) was calculated by divid
tracks counted for each sample as shown in left panels were calculated. Values are means ± s
Student's t-test. b. For the control experiment in which knockdown of DNA2 was employed,
the cells to restart replication after CPT or HU fork stalling was determined as in panel a. Wes
(Figure S5). In both panels a and b, red tracks represent synthesis before addition of HU or C
tracks represent initiations after removal of HU or CPT. c–d. C5 prevents single-stranded DNA
with HU at similar level as DNA2 knockdown. c. Cells with more than 15 P-RPA foci indicative
or BOD1L or scrambled siRNA, as indicated, followed by treatment with 4 mM hydroxyurea (H
C5 (20 μM). In the absence of HU, no cells with greater than 15 foci were observed. d. Cells w
transfected with siRNA against BRCA2 or scrambled siRNA, as indicated, followed by treatme
against DNA2. In both c and d, top panels show the representative immunoﬂuorescence im
Values were calculated with the Student's t-test. Western blots of knockdowns are shown in Fwhen replication forks stalled at the endogenous FOB1 protein-
mediated replication fork barrier in the rDNA (Weitao et al., 2003a, b).
In Schizosaccharomyces pombe, furthermore, it was shown that DNA2
was acted on by the checkpoint to prevent fork collapse upon stalling
at a similar barrier (Hu et al., 2012). More recently, human DNA2 has
been shown in elegant DNA spreading experiments using knockdowns
to be crucial for restart of forks stalled by CPT and speciﬁcally ton cells defective in fork protection (see also Figure S6). a. and b. C5 inhibits DNA replication
C5 (20 μM) for 2 h, labeled with IdU (red) for 30 min, and co-cultured with IdU and the
bined with 150 nM CPT or 2 mM HU) for 1 h, and then washed and labeled with CIdU
ing the red-green tracks by the sum of the red-green and red only tracks. At least 150
.d. from three independent experiments (right panel). The p value was calculated by the
A549 cells were transfected with scrambled or DNA2 siRNAs for 72 h, and the ability of
tern blotting conﬁrmed an efﬁcient knockdown of DNA2 at 72 h post siRNA transfections
PT. Red/green tracks represent molecules that recovered from fork stalling. Green only
accumulation in BOD1L-depleted or BRCA2-depleted U2OS cells upon replication stalling
of single-stranded DNA were scored in U2OS cells transfected with siRNA against BRCA2
U) for 5 h. Cells were pretreated with MRE11 inhibitor mirin (50 μM) or DNA2 inhibitor
ith more than 15 P-RPA foci indicative of single-stranded DNA were scored in U2OS cells
nt with 4 mM HU for 5 h. Cells were pretreated with MRE11 inhibitor, PFM39 or siRNA
ages, and the bottom panel shows the quantiﬁcations. Error bars represent the SEM. p-
igure S6.
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This activity must be tightly controlled, however, because the restora-
tion of fork protection by inhibition of DNA2 in both BRCA2- and
BOD1L depleted cells, at very low levels of the DNA2 inhibitor C5
(20 μM) and to the same extent as knockdown of DNA2 (Fig. 6), con-
ﬁrms previous reports that, if not properly regulated, over-resection
by DNA2 can lead to excessive fork degradation and genome instability
(Wang et al., 2015; Higgs et al., 2015). This coincides with the demon-
stration that depletion of DNA2 can suppress the cisplatin sensitivity
of FANCD2−/− cells, which we proposed was due to over-resection at
stalled forks (Karanja et al., 2014). By contrast to these replication func-
tions, we found that higher levels of C5 were required to achieve the
same level of inhibition as by knockdown of DNA2 (Fig. 5) when mea-
suring SSA and HR in the GFP reporter assays, which are not thought
to depend on on-going replication,
Until this study, there were no known small molecule inhibitors of
DNA2. Discovering and testing additional DNA2 inhibitors will not
only be invaluable for characterizing the integrated DNA2 enzymatic ac-
tivities but will also enhance the preparation of advanced inhibitors for
anticancer regimens, either alone or in combination with other chemo-
therapeutics. Importantly, chemical inhibition of DNA2 displayed cyto-
toxicity to DNA2-proﬁcient mouse and human cells but not toward
dna2−/−MES DNA2-deﬁcient cells of human cells after DNA2 knock-
down, supporting the assertion that we have found a DNA2-speciﬁc in-
hibitor. The use of inhibitors plusmutations to elucidate themechanism
of DNA2 nuclease/helicase activation as a basis for understanding its
regulation in vivo is critical to design new therapeutic regimens. Inhib-
itors allow one to monitor the acute response of cells to the absence of
DNA2,which is an important distinction fromgenetic studies, whose in-
terpretation is always made difﬁcult when studying essential genes
such as DNA2. In the current study, we tested if targeting DNA2may ex-
ploit a speciﬁc vulnerability in the cancer cells, assuming that normal
cells are better protected by intact checkpoints and redundant repair
processes.
We also tested the possible potentiation of PARP inhibitors by DNA2
inhibitor C5, because previous work suggested that DNA2 and PARP
might participate in overlapping repair and replication stress response
pathways (Bryant et al., 2009; Wanrooij and Burgers, 2015; Yang
et al., 2004; Ying et al., 2012). PARP inhibitors have proved promising
in treating BRCA-deﬁcient tumors but fall short in that many such tu-
mors are resistant. We tested if DNA2 might be partially responsible
by performing a complementary function using the C5 DNA2 inhibitor.
Indeed, C5 potentiated PARPi and vice versa. This “synthetic lethality”
suggests novel approaches to applications of PARPi therapy. It also in-
creases conﬁdence that DNA2 and PARP function in response to replica-
tion stress that might occur in response to oncogene activation or
treatment with DNA damaging agents such as CPT. Our demonstration
of the stimulation of PARP inhibition by C5 may suggest that DNA2
plays a complementary role with PARP at stalled replication forks,
where PARP has been shown to mediate replication fork restart in con-
junction with MRE11, a nuclease that acts upstream of DNA2 in resec-
tion functions (Shibata et al., 2014; Bryant et al., 2009). In sum, the
data presented here show that DNA2 inhibitors sensitize cancer cells
to DNA damaging agents and additional agents used in current therapy
and therefore may be feasible anti-cancer agents.
Funding Sources
The work was supported by an NIH grant RO1 CA085344, the
Margaret E. Early Medical Research Trust grant ADF-1481M to B.H.S.,
Margaret Early Medical Research Trust grant and ARO W81XWH-09-
1-0041 to J.L.C., a Caltech-City of Hope Biomedical Research Initiative
to B.H.S. and J.L.C., and K22 grant 5K22CA175262–04 to K.S. Wenpeng
Liu is supported by the China Scholarship Council (CSC) during his
visit to California Institute of Technology and City of Hope, and K.S. is a
CPRIT scholar in cancer biology.Conﬂict of Interest Statement
We declare no ﬁnancial or other relationships that may lead to a
conﬂict of interest in this study.
Author Contributions
L.Z., J.L.C. and B.S. designed the study and supervised the entire pro-
ject. L.Z., J.L.C., B.S. and K.S. wrote themanuscript. H.L. established the 3-
D model and virtually screened the chemical inhibitors. W.L., P.P., J.L.C.,
Q.W., C.L, and K.K.J. puriﬁed the proteins and performed all of the bio-
chemical experiments in the current study. K.S. and V.P. designed and
executed the fork protection experiments. Z.L. performed the DNA
ﬁber experiments. Correspondence concerning fork protection experi-
ments may be addressed to K.S. and V.P. M.Z., Z.L., H.D., K.K.J., L.C., per-
formed the cellular functional (SSA, HR, P-RPA resection, replication
fork restart) and toxicological assays. S.S. supervised the enzyme kinet-
ics experiments.
Acknowledgments
We thank the City of Hope Microscopy and Bioinformatics Core Fa-
cilities, National Cancer Institute (NCI) designated cancer center sup-
port grant P30 CA033572, and Nancy Linford, Ph.D. for her critical
reading and editing of the manuscript and S. Howard and J. Stark for
their technical support.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.02.043.
References
Bae, S.H., Bae, K.-H., Kim, J.A., Seo, Y.S., 2001. RPA governs endonuclease switching during
processing of Okazaki fragments in eukaryotes. Nature 412, 456–461.
Bae, S.-H., Kim, D.W., Kim, J., Kim, J.-H., Kim, D.-H., Kim, H.-D., Kang, H.-Y., Seo, Y.-S., 2002.
Coupling of DNA helicase and endonuclease activities of yeast Dna2 facilitates Okaza-
ki fragment processing. J. Biol. Chem. 277, 26632–26641.
Balakrishnan, L., Polaczek, P., Pokharel, S., Campbell, J.L., Bambara, R.A., 2010. Dna2 ex-
hibits a unique strand end-dependent helicase function. J. Biol. Chem. 285,
38861–38868.
Begg, A.C., Stewart, F.A., Vens, C., 2011. Strategies to improve radiotherapy with targeted
drugs. Nat. Rev. Cancer 11, 239–253.
Bryant, H.E., Petermann, E., Schultz, N., Jemth, A.S., Loseva, O., Issaeva, N., Johansson, F.,
Fernandez, S., Mcglynn, P., Helleday, T., 2009. PARP is activated at stalled forks to
mediate Mre11-dependent replication restart and recombination. EMBO J. 28,
2601–2615.
Budd, M.E., Campbell, J.L., 1995. A new yeast gene required for DNA replication encodes a
protein with homology to DNA helicases. Proc. Natl. Acad. Sci. U. S. A. 92, 7642–7646.
Budd, M.E., Campbell, J.L., 1997. A yeast replicative helicase, Dna2 helicase, interacts with
yeast FEN-1 nuclease in carrying out its essential function. Mol. Cell. Biol. 17,
2136–2142.
Budd, M.E., Campbell, J.L., 2000. The pattern of sensitivity of yeast dna2 mutants to DNA
damaging agents suggests a role in DSB and postreplication repair pathways.
Mutat. Res. 459, 173–186.
Budd, M.E., Campbell, J.L., 2009. Interplay of Mre11 nuclease with Dna2 plus Sgs1 in
Rad51-dependent recombinational repair. PLoS One 4, e4267.
Budd, M.E., Tong, A.H., Polaczek, P., Peng, X., Boone, C., Campbell, J.L., 2005. A network of
multi-tasking proteins at the DNA replication fork preserves genome stability. PLoS
Genet. 1, 634–650.
Cejka, P., Cannavo, E., Polaczek, P., Masuda-Sasa, T., Pokharel, S., Campbell, J.L.,
Kowalczykowski, S.C., 2010. DNA end resection by Dna2-Sgs1-RPA and its stimula-
tion by Top3-Rmi1 and Mre11-Rad50-Xrs2. Nature 467, 112–116.
Chakrabarti, S., Jayachandran, U., Bonneau, F., Fiorini, F., Basquin, C., Domcke, S., Le Hir, H.,
Conti, E., 2011. Molecular mechanisms for the RNA-dependent ATPase activity of
Upf1 and its regulation by Upf2. Mol. Cell 41, 693–703.
Chen, M.C., Zhou, B., Zhang, K., Yuan, Y.C., Un, F., Hu, S., Chou, C.M., Chen, C.H., Wu, J.,
Wang, Y., Liu, X., Smith, D.L., Li, H., Liu, Z., Warden, C.D., Su, L., Malkas, L.H., Chung,
Y.M., Hu, M.C., Yen, Y., 2015. The novel ribonucleotide reductase inhibitor COH29 in-
hibits DNA repair in vitro. Mol. Pharmacol. 87, 996–1005.
Cheng, Z., Muhlrad, D., Lim, M.K., Parker, R., Song, H., 2007. Structural and functional in-
sights into the human Upf1 helicase core. EMBO J. 26, 253–264.
Chou, T.C., 2010. Drug combination studies and their synergy quantiﬁcation using the
Chou–Talalay method. Cancer Res. 70, 440–446.
85W. Liu et al. / EBioMedicine 6 (2016) 73–86Duxin, J.P., Dao, B., Martinsson, P., Rajala, N., Guittat, L., Campbell, J.L., Spelbrink, J.N.,
Stewart, S.A., 2009. Human Dna2 is a nuclear and mitochondrial DNA maintenance
protein. Mol. Cell. Biol. 29, 4274–4282.
Duxin, J.P., Moore, H.R., Sidorova, J., Karanja, K., Honaker, Y., Dao, B., Piwnica-Worms, H.,
Campbell, J.L., Monnat, R.J., Stewart, S.A., 2012. Okazaki fragment processing-
independent role for human Dna2 during DNA replication. J. Biol. Chem. 21980–21991.
Fathers, C., Drayton, R.M., Solovieva, S., Bryant, H.E., 2012. Inhibition of poly(ADP-ribose)
glycohydrolase (PARG) speciﬁcally kills BRCA2-deﬁcient tumor cells. Cell Cycle 11,
990–997.
Fisher, A.E., Hochegger, H., Takeda, S., Caldecott, K.W., 2007. Poly(ADP-ribose) polymerase
1 accelerates single-strand break repair in concert with poly(ADP-ribose)
glycohydrolase. Mol. Cell. Biol. 27, 5597–5605.
Fong, Y., Chou, S.J., Hung, K.F., Wu, H.T., Kao, S.Y., 2008. An investigation of the differential
expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia,
and oral squamous cell carcinoma in Taiwan. J. Chin. Med. Assoc. 71, 123–127.
Gunn, A., Stark, J.M., 2012. I-SceI-based assays to examine distinct repair outcomes of
mammalian chromosomal double strand breaks. Methods Mol. Biol. 920, 379–391.
Hashimoto, Y., Chaudhuri, A.R., Lopes, M., Costanzo, V., 2010. Rad51 protects nascent DNA
from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat.
Struct. Mol. Biol. 17, 1305–1311.
Hellman, L.M., Fried, M.G., 2007. Electrophoretic mobility shift assay (EMSA) for detecting
protein-nucleic acid interactions. Nat. Protoc. 2, 1849–1861.
Higgs, M.R., Reynolds, J.J., Winczura, A., Blackford, A.N., Borel, V., Miller, E.S., Zlatanou, A.,
Nieminuszczy, J., Ryan, E.L., Davies, N.J., Stankovic, T., Boulton, S.J., Niedzwiedz, W.,
Stewart, G.S., 2015. BOD1L Is required to suppress deleterious resection of stressed
replication forks. Mol. Cell 59, 462–477.
Hoa, N.N., Kobayashi, J., Omura, M., Hirakawa, M., Yang, S.H., Komatsu, K., Paull, T.T.,
Takeda, S., Sasanuma, H., 2015. BRCA1 and CtIP are both required to recruit Dna2 at
double-strand breaks in homologous recombination. PLoS One 10, e0124495.
Howard, S.M., Yanez, D.A., Stark, J.M., 2015. DNA damage response factors from diverse
pathways, including DNA crosslink repair, mediate alternative end joining. PLoS
Genet. 11, e1004943.
Hsiang, Y.H., Lihou, M.G., Liu, L.F., 1989. Arrest of replication forks by drug-stabilized topo-
isomerase I-DNA cleavable complexes as amechanism of cell killing by camptothecin.
Cancer Res. 49, 5077–5082.
Hu, Y., Petit, S.A., Ficarro, S.B., Toomire, K.J., Xie, A., Lim, E., Cao, S.A., Park, E., Eck, M.J.,
Scully, R., Brown, M., Marto, J.A., Livingston, D.M., 2014. PARP1-driven poly-ADP-
ribosylation regulates BRCA1 function in homologous recombination-mediated
DNA repair. Cancer Discov. 4, 1430–1447.
Hu, J., Sun, L., Shen, F., Chen, Y., Hua, Y., Liu, Y., Zhang, M., Hu, Y., Wang, Q., Xu, W., Sun, F.,
Ji, J., Murray, J.M., Carr, A.M., Kong, D., 2012. The intra-s phase checkpoint targets
dna2 to prevent stalled replication forks from reversing. Cell 149, 1221–1232.
Imamura, O., Campbell, J.L., 2003. The human Bloom syndrome gene suppresses the DNA
replication and repair defects of yeast dna2 mutants. Proc. Natl. Acad. Sci. U. S. A. 100,
8193–8198.
Jones, P., Altamura, S., Boueres, J., Ferrigno, F., Fonsi, M., Giomini, C., Lamartina, S.,
Monteagudo, E., Ontoria, J.M., Orsale, M.V., Palumbi, M.C., Pesci, S., Roscilli, G.,
Scarpelli, R., Schultz-Fademrecht, C., Toniatti, C., Rowley, M., 2009. Discovery of 2-
{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel
oral poly(ADP-ribose)polymerase (PARP) inhibitor efﬁcacious in BRCA-1 and -2 mu-
tant tumors. J. Med. Chem. 52, 7170–7185.
Kang, J.-Y., Choi, E., Bae, S.-H., Lee, K.-H., Gim, B.-S., Kim, H.-D., Park, C., Macneill, S.A., Seo,
Y.-S., 2000. Genetic analyses of Schizosaccharomyces pombe dna2+ reveal that Dna2
plays an essential role in Okazaki fragment metabolism. Genetics 155, 1055–1067.
Kang, Y.H., Lee, C.H., Seo, Y.S., 2010. Dna2 on the road to Okazaki fragment processing and
genome stability in eukaryotes. Crit. Rev. Biochem. Mol. Biol. 45, 71–96.
Kao, H.-I., Campbell, J.L., Bambara, R.A., 2004a. Dna2p helicase/nuclease is a tracking pro-
tein, like FEN1, for ﬂap cleavage during Okazaki fragment maturation. J. Biol. Chem.
279, 50840–50849.
Kao, H.I., Veeraraghavan, J., Polaczek, P., Campbell, J.L., Bambara, R.A., 2004b. On the roles
of Saccharomyces cerevisiae Dna2p and FEN1 in Okazaki fragment processing. J. Biol.
Chem. 279, 15014–15024.
Karanja, K.K., C, S.W., Duxin, J.P., Stewart, S.A., Campbell, J.L., 2012. DNA2 and EXO1 in rep-
lication-coupled homology directed repair and in the interplay between HDR and the
FA/BRCA network. Cell Cycle 11, 3983–3996.
Karanja, K.K., Lee, E.H., Hendrickson, E.A., Campbell, J.L., 2014. Preventing over-resection
by DNA2 helicase/nuclease suppresses repair defects in Fanconi anemia cells. Cell
Cycle 13, 1540–1550.
Kim, D.-H., Lee, K.-H., Kim, J.-H., Ryu, G.-H., Bae, S.-H., Lee, B.-C., Moon, K.-Y., Byun, S.-M.,
Koo, H.-S., Seo, Y.-S., 2005. Enzymatic properties of the Caenorhabditis elegans Dna2
endonuclease/helicase and a species-speciﬁc interaction between RPA and Dna2.
Nucleic Acids Res. 33, 1372–1383.
Kumar, S., Burgers, P.M., 2013. Lagging strand maturation factor Dna2 is a component of
the replication checkpoint initiation machinery. Genes Dev. 27, 313–321.
Lai, M.S., Foiani, M., 2012. Dna2 offers support for stalled forks. Cell 149, 1181–1183.
Le Tourneau, C., Stathis, A., Vidal, L., Moore, M.J., Siu, L.L., 2010. Choice of starting dose for
molecularly targeted agents evaluated in ﬁrst-in-human phase I cancer clinical trials.
J. Clin. Oncol. 28, 1401–1407.
Levikova, M., Klaue, D., Seidel, R., Cejka, P., 2013. Nuclease activity of Saccharomyces
cerevisiae Dna2 inhibits its potent DNA helicase activity. Proc. Natl. Acad. Sci. U. S.
A. E1992-2001.
Li, M., Yu, X., 2013. Function of BRCA1 in the DNA damage response is mediated by ADP-
ribosylation. Cancer Cell 23, 693–704.
Liao, S., Toczylowski, T., Yan, H., 2008. Identiﬁcation of the Xenopus DNA2 protein as a
major nuclease for the 5′–N3′ strand-speciﬁc processing of DNA ends. Nucleic Acids
Res. 36, 6091–6100.Liao, S., Toczylowski, T., Yan, H., 2011. Mechanistic analysis of Xenopus EXO1's function in
5′-strand resection at DNA double-strand breaks. Nucleic Acids Res. 39, 5967–5977.
Lin, W., Sampathi, S., Dai, H., Liu, C., Zhou, M., Hu, J., Huang, Q., Campbell, J., Shin-Ya, K.,
Zheng, L., Chai, W., Shen, B., 2013. Mammalian DNA2 helicase/nuclease cleaves G-
quadruplex DNA and is required for telomere integrity. EMBO J. 32, 1425–1439.
Masuda-Sasa, T., Imamura, O., Campbell, J.L., 2006. Biochemical analysis of human Dna2.
Nucleic Acids Res. 34, 1865–1875.
Masuda-Sasa, T., Polaczek, P., Peng, X.P., Chen, L., Campbell, J.L., 2008. Processing of G4
DNA by Dna2 helicase/nuclease and RPA provides insights into the mechanism of
Dna2/RPA substrate recognition. J. Biol. Chem. 283, 24359–24373.
Nimonkar, A.V., Genschel, J., Kinoshita, E., Polaczek, P., Campbell, J.L., Wyman, C., Modrich,
P., Kowalczykowski, S.C., 2011. BLM-DNA2-RPA-MRN- and EXO1-BLM-RPA-MRN
constitute two DNA end resection machineries for human DNA break repair. Genes
Dev. 25, 350–362.
Niu, H., Raynard, S., Sung, P., 2009. Multiplicity of DNA end resection machineries in chro-
mosome break repair. Genes Dev. 23, 1481–1486.
Okano, S., Lan, L., Caldecott, K.W., Mori, T., Yasui, A., 2003. Spatial and temporal cellular
responses to single-strand breaks in human cells. Mol. Cell. Biol. 23, 3974–3981.
Patel, A.G., Flatten, K.S., Schneider, P.A., Dai, N.T., Mcdonald, J.S., Poirier, G.G., Kaufmann,
S.H., 2012. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibi-
tors and topoisomerase I inhibitors reﬂects poisoning of both enzymes. J. Biol.
Chem. 287, 4198–4210.
Peng, G., Dai, H., Zhang, W., Hsieh, H.J., Pan, M.R., Park, Y.Y., Tsai, R.Y., Bedrosian, I., Lee, J.S.,
Ira, G., Lin, S.Y., 2012. Human nuclease/helicase DNA2 alleviates replication stress by
promoting DNA End resection. Cancer Res. 72, 2802–2813.
Petermann, E., Orta, M.L., Issaeva, N., Schultz, N., Helleday, T., 2010. Hydroxyurea-stalled
replication forks become progressively inactivated and require two different
RAD51-mediated pathways for restart and repair. Mol. Cell 37, 492–502.
Pierce, A.J., Johnson, R.D., Thompson, L.H., Jasin, M., 1999. XRCC3 promotes homology-
directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633–2638.
Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K.J., Fachinetti, D., Bermejo, R.,
Cocito, A., Costanzo, V., Lopes, M., 2012. Topoisomerase I poisoning results in PARP-
mediated replication fork reversal. Nat. Struct. Mol. Biol. 19, 417–423.
Ronchi, D., Di Fonzo, A., Lin, W., Bordoni, A., Liu, C., Fassone, E., Pagliarani, S., Rizzuti, M.,
Zheng, L., Filosto, M., Ferro, M.T., Ranieri, M., Magri, F., Peverelli, L., Li, H., Yuan, Y.C.,
Corti, S., Sciacco, M., Moggio, M., Bresolin, N., Shen, B., Comi, G.P., 2013. Mutations
in DNA2 link progressive myopathy to mitochondrial DNA instability. Am. J. Hum.
Genet. 92, 293–300.
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., Jasin, M., 2011. Double-strand break
repair-independent role for BRCA2 in blocking stalled replication fork degradation by
MRE11. Cell 145, 529–542.
Schlacher, K., Wu, H., Jasin, M., 2012. A distinct replication fork protection pathway con-
nects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106–116.
Shaheen, R., Faqiih, E., Ansari, S., Abdel-Salam, G., Al-Hassnan, Z.N., Al-Shidi, T., Alomar, R.,
Sogaty, S., Alkuraya, F.S., 2014. Genomic analysis of primorial dwarﬁsm reveals novel
disease genes. Genome Res. 24, 291–299.
Shibata, A., Moiani, D., Arvai, A.S., Perry, J., Harding, S.M., Genols, M.-M., Maity, R., Rossum-
Fikkert, S.V., Kertokallo, A., Romoli, F., Ismail, A., Ismalaj, E., Petricci, E., Neale, M.J.,
Bristorw, R.G., Masson, J.-Y., Wyman, C., Jeggo, P.A., Tainer, J.A., 2014. DNA Double-
Strand break repair pathway choice is directed by distinct MRE11 nuclease activities.
Mol. Cell 53, 7–18.
Stewart, J.A., Campbell, J.L., Bambara, R.A., 2010. Dna2 is a structure-speciﬁc nuclease,
with afﬁnity for 5′-ﬂap intermediates. Nucleic Acids Res. 38, 920–930.
Stewart, J.A., Miller, A.S., Campbell, J.L., Bambara, R.A., 2008. Dynamic removal of replica-
tion protein A by Dna2 facilitates primer cleavage during Okazaki fragment process-
ing in Saccharomyces cerevisiae. J. Biol. Chem. 283, 31356–31365.
Strauss, C., Kornowski, M., Benvenisty, A., Shahar, A., Masury, H., Ben-Porath, I., Ravid, T.,
Arbel-Eden, A., Goldberg, M., 2014. The DNA2 nuclease/helicase is an estrogen-
dependent gene mutated in breast and ovarian cancers. Oncotarget 5, 9396–9409.
Sturzenegger, A., Burdova, K., Kanagaraj, R., Levikova, M., Pinto, C., Cejka, P., Janscak, P.,
2014. DNA2 cooperates with the WRN and BLM RecQ helicases to mediate long-
range DNA end resection in human cells. J. Biol. Chem. 289, 27314–27326.
Symington, L.S., Gautier, J., 2011. Double-Strand break end resection and repair pathway
choice. Annu. Rev. Genet. 45, 247–271.
Teicher, B.A., 2008. Next generation topoisomerase I inhibitors: rationale and biomarker
strategies. Biochem. Pharmacol. 75, 1262–1271.
Thangavel, S., Berti, M., Levikova, M., Pinto, C., Gomathinayagam, S., Vujanovic, M.,
Zellweger, R., Moore, H., Lee, E.H., Hendrickson, E.A., Cejka, P., Stewart, S., Lopes, M.,
Vindigni, A., 2015. DNA2 drives processing and restart of reversed replication forks
in human cells. J. Cell Biol. 208, 545–562.
Wang, A.T., Kim, T., Wagner, J.E., Conti, B.A., Lach, F.P., Huang, A.L., Molina, H., Sanborn,
E.M., Zierhut, H., Cornes, B.K., Abhyankar, A., Sougnez, C., Gabriel, S.B., Auerbach,
A.D., Kowalczykowski, S.C., Smogorzewska, A., 2015. A dominant mutation in
human RAD51 reveals its function in DNA Interstrand crosslink repair independent
of homologous recombination. Mol. Cell 59, 478–490.
Wanrooij, P.H., Burgers, P.M., 2015. Yet another job for Dna2: checkpoint activation. DNA
Repair (Amst) 32, 17–23.
Wawrousek, K.E., Fortini, B.K., Polaczek, P., Chen, L., Liu, Q., Dunphy, W.G., Campbell, J.L.,
2010. Xenopus DNA2 is a helicase/nuclease that is found in complexes with replica-
tion proteins and-1/Ctf4 and Mcm10 and DSB response proteins Nbs1 and ATM. Cell
Cycle 9, 1156–1166.
Weitao, T., Budd, M., Campbell, J.L., 2003a. Evidence that yeast SGS1, DNA2, SRS2, and FOB1
interact to maintain rDNA stability. Mutat. Res. 532, 157–172.
Weitao, T., Budd, M., Hoopes, L.L., Campbell, J.L., 2003b. Dna2 helicase/nuclease causes
replicative fork stalling and double-strand breaks in the ribosomal DNA of Saccharo-
myces cerevisiae. J. Biol. Chem. 278, 22513–22522.
86 W. Liu et al. / EBioMedicine 6 (2016) 73–86Yang, Y.G., Cortes, U., Patnaik, S., Jasin, M., Wang, Z.Q., 2004. Ablation of PARP-1 does not
interferewith the repair of DNA double-strand breaks, but compromises the reactiva-
tion of stalled replication forks. Oncogene 23, 3872–3882.
Ying, S., Hamdy, F.C., Helleday, T., 2012. Mre11-dependent degradation of stalled DNA
replication forks is prevented by BRCA2 and PARP1. Cancer Res. 72, 2814–2821.
Zheng, L., Zhou, M., Guo, Z., Lu, H., Qian, L., Dai, H., Qiu, J., Yakubovskaya, E., Bogenhagen,
D.F., Demple, B., Shen, B., 2008. Human DNA2 is a mitochondrial nuclease/helicase for
efﬁcient processing of DNA replication and repair intermediates. Mol. Cell 32,
325–336.
Zhou, C., Pourmal, S., Pavletich, N.P., 2015. Dna2 nuclease-helicase structure, mechanism
and regulation by RPA. Elife 4.Zhou, B., Su, L., Hu, S., Hu, W., Yip, M.L., Wu, J., Gaur, S., Smith, D.L., Yuan, Y.C., Synold, T.W.,
Horne, D., Yen, Y., 2013. A small-molecule blocking ribonucleotide reductase holoen-
zyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer
Res. 73, 6484–6493.
Zhu, Z., Chung, W.H., Shim, E.Y., Lee, S.E., Ira, G., 2008. Sgs1 helicase and two nucleases
Dna2 and Exo1 resect DNA double-strand break ends. Cell 134, 981–994.
Zou, L., Elledge, S.J., 2003. Sensing DNA damage through ATRIP recognition of RPA–ssDNA
complexes. Science 300, 1542–1548.
